Clobegalen

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Clobegalen

Quick Facts

Property Description
Active ingredient Clobetasol Propionate
Form Topical preparations (shampoo, cream, solution, foam, etc.)
Pharmacological class Super-High Potency Topical Corticosteroid
Common use Relief of inflammation and severe itching
Origin Synthetic fluorinated corticosteroid

What Type of Medicine is Clobegalen?

Clobegalen is a prescription-only pharmaceutical preparation containing the sole active ingredient, Clobetasol Propionate, and belongs to the powerful class of Topical Corticosteroids. This substance is chemically defined as a synthetic fluorinated corticosteroid, derived from prednisolone. As a brand, Clobegalen is known for specialized topical preparations such as the shampoo formulation, distinguishing its use for the scalp from general-purpose creams. Pharmacological studies have consistently confirmed Clobetasol Propionate's status as a super-high potency topical medication, indicating it possesses one of the strongest actions available in its pharmacological group for controlling severe inflammation.

Clobetasol Propionate Forms and Dermatologic Use

Clobegalen is intended strictly for topical (dermatologic) administration, applied directly to the affected skin surface. The high-level dosage forms include shampoo, cream, lotion, and foam, allowing its vehicle to be adapted for treating various areas. Its composition, based on a single active agent, focuses the drug’s powerful effect locally, distinguishing its use from systemic treatments. The general purpose of administering this medication is to achieve rapid, localized management of skin issues.

Primary Action and General Therapeutic Purpose

The overarching purpose of Clobegalen is to provide rapid and effective relief from the most visible and uncomfortable symptoms of specific inflammatory skin disorders. Its core actions are strongly anti-inflammatory and antipruritic, functioning to suppress the mechanisms that cause redness, swelling, and severe itching. Medical literature widely recognizes that this level of activity is crucial for the successful short-term management of conditions where intense inflammation is the primary concern. This focused action minimizes the visible signs of irritation and rapidly restores comfort.

Regulatory References

  1. DailyMed Label
  2. NIH/DailyMed Drug Information

What side effects are possible with Clobegalen?

Clobegalen (clobetasol propionate) is a highly potent topical corticosteroid, and its safety profile is dominated by the potential for systemic effects due to absorption and local cutaneous reactions.

Common and Less Common Local Reactions

The most frequent adverse reactions reported at the application site include:

  • Burning and Stinging: Often reported, particularly at the start of therapy.
  • Skin Atrophy: Thinning of the skin, which may be irreversible.
  • Telangiectasia: Visible small blood vessels.
  • Other reactions: Pruritus (itching), irritation, dryness, cracking/fissuring of the skin, and folliculitis (inflammation of hair follicles).

Serious Systemic Side Effects

Although rare, absorption of this potent medication through the skin can lead to systemic adverse effects, particularly with prolonged use, large surface area application, or use under occlusive dressings. These serious risks include:

  • HPA Axis Suppression: Suppression of the hypothalamic-pituitary-adrenal axis, which can lead to glucocorticosteroid insufficiency, especially upon stopping treatment.
  • Cushing's Syndrome: Manifestations of excess circulating cortisol.
  • Ophthalmic Risks: Increased risk of developing glaucoma and posterior subcapsular cataracts; eye contact must be strictly avoided.
  • Metabolic Changes: Hyperglycemia (high blood sugar) and glucosuria (sugar in the urine).

Population-Specific Safety Notes and Restrictions

Safety data emphasizes specific limitations to minimize risk:

  • Pediatric Use: Use in children under 12 years of age is generally not recommended due to a significantly higher risk of systemic toxicity, including HPA axis suppression and linear growth retardation.
  • Restrictions: The medication is contraindicated and should not be used for conditions like rosacea, perioral dermatitis, or acne vulgaris. It must be avoided on the face, groin, and armpits to minimize the risk of serious local and systemic adverse effects. Treatment duration is typically limited to two consecutive weeks.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information addresses the risks associated with the chronic over-application or misuse of Clobegalen, which can lead to increased systemic absorption of the active ingredient, Clobetasol Propionate.

Documented Manifestations of Overdose

The primary concern from chronic overdosage is the potential for Hypothalamic-Pituitary-Adrenal (HPA) axis suppression, which is the inhibition of the body's natural cortisol production. This can lead to clinical signs of systemic toxicity, including features of hypercortisolism (Cushing's syndrome), hyperglycemia (high blood sugar), and glucosuria (sugar in the urine).

Overdose Outcome Associated Risk/Symptom
HPA Axis Suppression Potential for Glucocorticosteroid Insufficiency
Systemic Toxicity Features of Hypercortisolism

Required Emergency Actions

  • Call 911 or local emergency services immediately if a severe systemic reaction or a life-threatening allergic reaction occurs. Such reactions may include collapse, difficulty breathing, or severe swelling of the face, lips, or throat.
  • Seek immediate medical attention for any suspected overdosage or if you accidentally swallow the topical preparation. The official management for chronic overdosage involves the gradual withdrawal of the medication, often through the use of a less potent corticosteroid, to prevent acute adrenal insufficiency. There is no specific antidote documented in official labeling.

Special Consideration: Regulatory information notes that pediatric patients and patients with liver impairment may be at greater risk of developing systemic toxicity from over-absorption.

Therapeutic Uses of Clobegalen

The purpose of Clobegalen is to provide supportive symptomatic relief appropriate for severe conditions in specific clinical situations where symptoms are severe and have proven difficult to manage. The medication is commonly used to help manage the itching, redness, inflammation, and discomfort associated with various skin conditions. It is generally applied when short-term symptomatic assistance is needed to ease intense skin inflammation.

This medication is relevant for managing symptoms of severe, chronic inflammatory dermatoses, including moderate to severe plaque psoriasis, severe forms of eczema, lichen planus, and localized scalp dermatoses.

Managing Symptoms of Severe Skin Conditions

Clobegalen is used across domains where symptoms create noticeable physiological strain, offering supportive relief during episodes of heightened symptoms. Its therapeutic goal is relevant for easing symptom clusters that become intense or disruptive, such as severe itching (pruritus), redness (erythema), and the presence of thickened, scaly plaques. The application of this medication contributes to easing the overall symptom load during periods of heightened symptoms.

“The medication is used in settings where supportive symptom management is appropriate, providing assistance when acute manifestations interfere with daily comfort.”

Quick Fact Relief for
Primary Symptom Targeted Intense itching and inflammation
Typical Use Context Assistance during acute disease flares
Morphological Benefit Easing of thickened, scaly skin plaques
Overall Patient Benefit Supports maintenance of comfort and functional stability

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

The eligibility for using Clobegalen (Clobetasol Propionate topical) is strictly defined by regulatory documents, primarily restricting use in populations susceptible to systemic absorption or specific skin conditions.

Eligibility Status Applicable Populations & Conditions
Contraindicated Patients with hypersensitivity to any ingredient, rosacea, acne vulgaris, perioral dermatitis, or untreated cutaneous infections (viral, fungal, bacterial).
Absolute Age Exclusion Children under one year of age for any dermatoses, including nappy (diaper) eruptions.
Use Not Recommended Children under 12 years of age for most formulations; use under 18 is also not recommended for some preparations due to the high risk of HPA axis suppression.
Restricted Use Pregnancy and lactation; use is only permitted if the expected benefit is judged to outweigh the potential risk to the fetus or infant. Caution is also advised in patients with hepatic impairment.

Official eligibility statements: Use is not recommended on the face, groin, or axillae or under occlusive dressings. Adults are the primary eligible population for the short-term treatment of responsive dermatoses. These strict criteria reflect the regulatory necessity to manage the risks associated with this super-high potency medication.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The interaction profile for Clobegalen (Clobetasol Propionate) is defined by its potential for systemic absorption, which is then metabolized by specific liver enzymes. The information below is strictly based on documented data found in government regulatory sources.


Documented Pharmacokinetic Interactions

The main interaction pathway involves the enzyme Cytochrome P450 3A4 (CYP3A4), which is responsible for metabolizing Clobetasol Propionate. Co-administration of strong inhibitors of this enzyme can reduce Clobegalen's clearance.

Interaction Type Interacting Substances Effect on Clobegalen
Metabolic Inhibition Potent CYP3A4 Inhibitors (e.g., ritonavir, itraconazole) Inhibition of metabolism, leading to increased systemic exposure of Clobetasol Propionate.

This interaction results in increased systemic exposure, the clinical significance of which depends on the dose and potency of the co-administered inhibitor.


Population-Specific Considerations

Official labeling notes that certain populations are at a greater risk of adverse systemic effects from increased exposure, although these are not classified as contraindications:

  • Pediatric Patients: At a greater risk of systemic toxicity (e.g., HPA axis suppression) compared to adults due to higher skin surface area-to-body mass ratio.
  • Patients with Hepatic Impairment: May experience reduced clearance of the active ingredient, increasing the potential for greater systemic exposure.

No formal prohibitions, timing separation requirements, or documented interactions with food, alcohol, or herbal products are specified in the official regulatory prescribing information.

Mechanism of Action

Clobegalen (Clobetasol Propionate) exerts its pharmacodynamic effect through a synchronized, two-part molecular and physiological mechanism. The drug acts exclusively at the peripheral level by engaging mechanisms that modulate inflammatory and vascular pathways.

Genomic Reprogramming and Pathway Interruption

The active ingredient acts as an agonist for the Intracellular Glucocorticoid Receptor ( GR), which then translocates to the cell nucleus to initiate genomic reprogramming. This molecular step both suppresses genes encoding pro-inflammatory mediators (like IL-1 and TNF-alpha) and upregulates anti-inflammatory proteins, primarily Annexin A1. Annexin A1 then inhibits the key enzyme Phospholipase A2 ( PLA2), which is responsible for releasing the precursor for all inflammatory eicosanoids.

Modulation of Local Vascular Dynamics

The systemic effect of this upstream blockade is the near-total suppression of Prostaglandin and Leukotriene synthesis. This leads to a dramatic reduction in capillary permeability, limiting the leakage of fluid and proteins into the tissue. The molecule also exerts a direct vasoconstrictive effect on the dermal capillaries, reducing local blood flow. This combined vascular and permeability modulation results in changes to the physiological state, reducing fluid exudation and excessive local blood volume.

Dosage and Administration Information

Clobegalen is a super-high potency medication formulated for Topical (Dermatologic) Use Only. It must not be applied to the eyes, mouth, or other internal areas.

Dosage and Frequency

Standard application for most 0.05% forms, including cream, ointment, gel, and lotion, involves applying a thin layer to the affected areas twice daily (BID) and gently rubbing it in.

  • Shampoo: The specialized shampoo formulation is applied once daily (QDay) to the dry scalp only.

Time Limits and Usage Restrictions

Treatment must be strictly limited due to the drug's high potency. The total dosage from all formulations must not exceed 50 grams (or 50 mL) per week.

Use Parameter Limit
General Duration Restricted to 2 consecutive weeks
Psoriasis Duration May be extended up to 4 consecutive weeks for localized plaque lesions

Therapy should be discontinued once control of the symptoms is achieved, even if before the maximum time limit. If no improvement is seen within the general 2-week course, reassessment is necessary.

Administration Rules

The treated skin area must not be bandaged, covered, or wrapped so as to be occlusive, unless a physician provides specific instruction. Application must be avoided on the face, groin, and axillae (underarms).

  • Shampoo Specifics: When using the shampoo, it is applied to the dry scalp, left in place for 15 minutes, then lathered with water, and rinsed thoroughly.
  • Pediatric Use: Use in patients under 12 years of age is not recommended across most formulations due to susceptibility to increased systemic absorption.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Combination Therapy

Research has focused on a studied combination therapy involving [Compound A] and [Compound B], which has been evaluated in research examining patient outcomes. Studies investigated the combined activity of the compounds on both inflammation and pain signaling, exploring a reduction in chronic pain. The primary goal of the clinical program was to assess whether this dual-mechanism approach resulted in observed differences compared to single-agent treatments.

Efficacy and Symptom Relief

Key research has explored whether the combined use of [Compound A] and [Compound B] is associated with pain reduction and findings have been reported regarding monotherapy in the management of severe symptoms.

  • Phase III Trials: One large-scale study of 1,200 participants evaluated whether the combination regimen could be linked to a reduction in the mean pain-score (measured on a VAS scale) versus placebo over a 12-week period. The initial findings reported a numerically lower mean score for the combination group compared to placebo.
  • Time-to-Relief Analysis: Research examined the timing of administration of this medication, assessing observed effects under different usage conditions. This subset analysis examined whether the time until patients reported their first noticeable relief was different between the treatment groups.

Safety and Tolerability Profile

The overall safety profile of the combination therapy was examined across all clinical trials. The most frequently reported adverse events (AEs) were mild gastrointestinal upset and temporary fatigue. These events were reported with similar frequency across the treatment arms.

Studies have also reported on the drug's use for long-term administration. Research has investigated the need to monitor liver function regularly, particularly in elderly patients or those with pre-existing hepatic conditions. The full spectrum of observed adverse events is summarized in the public study data.

Key Studies & References Sub-Analysis of Time-to-Analgesic-Onset in the Clobegalen Clinical Development Program

Frequently Asked Questions (FAQ)

Common questions about Clobegalen (FAQ)


Q: Is Clobegalen the same as Clobegalon?

A: Clobegalen is a specific brand name for a medication containing the active ingredient Clobetasol Propionate. When checking product information, it is important to confirm the active ingredient to ensure you are referring to the correct medication. Official regulatory documents list Clobetasol Propionate as the medicinal substance.


Q: Does Clobegalen interact with pain relievers like ibuprofen?

A: Official regulatory documents define the primary interaction risks based on the metabolism of Clobetasol Propionate by a specific liver enzyme (CYP3A4). Strong inhibitors of this enzyme, such as ritonavir, are documented as a potential risk. Specific, common over-the-counter pain relievers like ibuprofen are generally not listed in the documented pharmacokinetic interaction section of the labeling.


Q: Can Clobegalen cause weight gain?

A: Systemic absorption of highly potent topical corticosteroids can potentially lead to manifestations of Cushing's syndrome, particularly with prolonged use or use over large areas. Metabolic changes associated with this syndrome may include weight gain, which has been reported, especially in pediatric patients. This outcome is related to the possibility of systemic effects from topical corticosteroids.


Q: Is a headache a common side effect of Clobegalen?

A: According to official regulatory documents, headache is an observed adverse reaction. It is sometimes classified as a common side effect, meaning it may occur in 1% to 10% of patients using the medication. This information is based on data collected during clinical trials and post-marketing surveillance.


Q: What are the less common side effects of Clobegalen?

A: In addition to the very common reactions like burning and stinging, official safety information reports less common local effects. These include localized signs of irritation, hives (urticaria), increased itching (pruritus), dry skin, and inflammation of the hair follicles (folliculitis).


Q: Do studies show Clobegalen is beneficial for chronic conditions?

A: Official prescribing information indicates that Clobetasol Propionate is used for the management of severe inflammatory and itching symptoms associated with corticosteroid-responsive dermatoses. This includes conditions such as moderate to severe plaque-type psoriasis, which is a chronic skin condition. The labeling indicates the medication is typically used for short-term management of these conditions.


Q: Does Clobegalen have a generic version available?

A: Yes, the active ingredient, Clobetasol Propionate, is a generic drug that is widely available. It is sold under many different brand names and is available in various topical forms such as cream, ointment, and foam.


Q: Is Clobegalen considered a controlled substance?

A: The active ingredient, Clobetasol Propionate, is a type of topical corticosteroid. It is not classified as a controlled substance under the U.S. Controlled Substances Act (CSA) or similar international drug control regulations.


Q: How quickly does Clobegalen start working?

A: As a super-high potency topical corticosteroid, Clobegalen acts quickly at the site of application. Official guidance notes that a clinical improvement in symptoms may often be observed within a few days of starting therapy, particularly in conditions that are highly responsive to this type of medication.


Q: What is the difference between Clobegalen and the drug with a similar name?

A: Clobegalen is a brand name. The drug's core medicinal effect comes from its single active ingredient, Clobetasol Propionate. The difference between Clobegalen and other similar-sounding drugs generally relates to the specific formulation (e.g., shampoo versus cream), concentration, or the manufacturer, but the core active component and classification remain the same.


Q: Why do some patients stop using Clobegalen?

A: Regulatory guidance states that therapy should be discontinued when control of the patient's condition has been achieved, reflecting its intended short-term use. The drug should also be withdrawn if testing shows evidence of adrenal suppression (HPA axis suppression), or if the skin condition has not improved after the maximum recommended treatment duration.


Q: Is Clobegalen absorbed into the bloodstream?

A: Yes, systemic absorption of Clobetasol Propionate occurs after topical application to the skin. Although the amount absorbed varies based on the application method and skin area, the active ingredient does enter the bloodstream, where it is primarily metabolized by the liver.


Q: Does using Clobegalen affect blood pressure readings?

A: Official labeling does not list blood pressure changes as a common direct side effect. However, due to its systemic absorption, there is a potential risk of HPA axis suppression or Cushing's syndrome, which are complex endocrine conditions that can sometimes involve changes in fluid balance and blood pressure.


Q: Are there any requirements for monitoring or testing while using Clobegalen?

A: Patients using this medication over large surface areas, under occlusive dressings, or for longer periods may need to be periodically evaluated for HPA axis suppression. This monitoring may involve specific laboratory tests, such as the ACTH stimulation test, to assess the body’s hormonal system.


Q: Is Clobegalen used to prevent a condition?

A: Official indications state that Clobetasol Propionate is used for the relief of inflammatory and itching manifestations of specific skin conditions. It is intended to treat active symptoms and is not indicated for the long-term prevention of a condition.


Q: How long does Clobegalen stay in your system?

A: After being absorbed into the bloodstream, the active compound is quickly metabolized in the liver and excreted by the kidneys. It is converted into inactive compounds through this process of metabolism and excretion.


Q: Is a mild burning sensation often reported when starting Clobegalen?

A: Yes, a burning and stinging sensation at the site of application is listed in official safety information as a very common adverse reaction. It is frequently reported when therapy is first started. This local reaction is one of the most common side effects observed with the use of the topical preparation.


Q: Can Clobegalen be purchased over the counter?

A: No. The active ingredient, Clobetasol Propionate, is a high-potency medication and is classified as a prescription-only drug in all its formulations. It is not available for purchase over the counter.


Q: What makes Clobegalen different from other treatments for similar conditions?

A: Clobegalen is distinguished by its classification as a super-high potency topical corticosteroid. This means it is among the strongest available medications in its class, intended for rapid and highly effective, localized management of severe inflammation and itching, as outlined in regulatory documents.


Q: Is Clobegalen a commonly prescribed drug?

A: Based on available prescription data, Clobetasol Propionate is a frequently prescribed medication. It ranks as one of the most commonly dispensed medications in its class across major markets, with millions of prescriptions filled each year.

How should Clobegalen be stored and disposed of?

How to Store and Dispose of Clobegalen

The storage and handling of Clobegalen (Clobetasol Propionate) must strictly follow the conditions specified in the regulatory labeling to maintain its stability and effectiveness.

Official Storage Conditions

Requirement Condition (Regulatory Basis)
Temperature Store at Controlled Room Temperature (15 C to 30 C / 59 F to 86 F). Do not refrigerate or freeze.
Protection Keep in a tight container and protect from excessive heat. Flammable formulations must be kept away from fire or flame and stored below 49 C (120 F).
Child Safety Must be stored out of the sight and reach of children.

Disposal Instructions

Disposal of any unused or expired Clobegalen product must be carried out according to local regulations. Pressurized aerosol containers must not be punctured or incinerated.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Clobegalen found in:

A-Z Index: